Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

APRI $2.39 0.3800 +18.91%
IMGN $14.21 1.4100 +11.02%
ARWR $12.39 0.9700 +8.49%
INFI $10.60 0.8100 +8.27%
FATE $7.25 0.5200 +7.73%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

GALT $10.28 -0.6400 -5.86%
TGTX $5.13 -0.2000 -3.75%
AGEN $2.41 -0.0700 -2.82%
IMNP $3.85 -0.0900 -2.28%
GHDX $26.83 -0.5800 -2.12%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Looming Ruling on Breast Cancer Drug Splits Patient Advocates

(CNNHealth) Sept 15, 2010 - Because Avastin is approved to treat other cancers, losing the breast cancer indication would not, technically, remove it from a doctor's toolkit. But here's the catch: Avastin costs more than $8,000 a month.
read article 



Prostate Screening Fails to Cut Cancer Deaths, Study Says

(Bloomberg) Sept 14, 2010 - Screening men for prostate cancer saves few lives and comes at the risk of unnecessary treatments, a study found.
read article 



Mayo Clinic Researchers Find Low-Cost HER2 Test, if Positive, All That is Needed

(Mayo Clinic) Sept 14, 2010 - They say the lower-cost protein test for Herceptin benefit is as good as the high price gene test.
read press release 



Calcium Deposits Could Improve Breast Cancer Diagnosis

(Cancer Research UK) Sept 15, 2010 - Scientists have discovered for the first time that studying calcium deposits in the breast, often detected through screening, could help doctors diagnose breast cancer more effectively.
read press release 



New Test Hope to Personalize Treatment for Bladder Cancer Patients

(Cancer Research UK) Sept 14, 2010 - Cancer Research UK scientists have identified a molecule in cells which could predict the success of radiotherapy to treat individual bladder cancer patients, reveals research published in Cancer Research today (Wednesday).
read press release 



BioCryst Pharma Presents Top-Line Data from Forodesine Phase 2 in CTCL and CLL

(StreetInsider) Sept 15, 2010 - BioCryst Pharmaceuticals, Inc. today announced preliminary top-line results from its multinational, open-label, single-arm trial evaluating 200 mg once-daily oral forodesine in the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL), as well as interim results from the Company’s exploratory Phase 2 study to investigate the efficacy and safety of 200 mg twice-daily oral forodesine as monotherapy for chronic lymphocytic leukemia (CLL).
read article 



Harbor BioSciences Apoptone(R) For Prostate Cancer Shows A Partial Overall Response

(TheStreet) Sept 14, 2010 - Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.
read article 



Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer

(Forbes) Sept 15, 2010 - Spirogen Limited and Celtic Therapeutics Holdings LP announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is being sponsored by the National Cancer Institute (NCI) of the USA, and is now actively recruiting patients for treatment.
read article 



Provectus Pharmaceuticals Completes Initial Enrollment in Phase 1 Trial of PV-10 for Liver Cancer

(SmartBrief) Sept 14, 2010 - Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.
read article 



Molecule 'Aids Breast Cancer Hope' Say Scientists

(BBC News) Sept 15, 2010 - The University of Aberdeen experts said the molecule in breast cancer cells could help identify the best treatment.
read article 



Cancer Patients and the Flu Vaccine

(Democrat and Chronicle) Sept 15, 2010 - Cancer patients, a large segment of the immunosuppressed population, are of particular concern.
read article 



Aetna Supports First National Study on Community-Based Use of Genetic Tests for Cancer Risk

(MarketWatch) Sept 15, 2010 - A landmark study, to be funded by Aetna, will explore patterns of how and for what groups of women the available genetic tests for BRCA1 and BRCA2 mutations are being used in the community health care setting, and whether, as suspected, significant disparities exist in the use of these tests among women of different socioeconomic, racial and ethnic groups.
read article 



Editorial: Medical Summit to Focus on Pediatric Cancer Fight

(Houston Chronicle) Sept 14, 2010 - Hundreds of billions of dollars are spent each year on cancer treatment and research, but studies and drug development specific to pediatric cancers remain woefully underfunded.
read article 



Millennium Sales Force Ranked #1 by Independent Survey of Leading Oncologists

(Yahoo! Finance) Sept 14, 2010 - Millennium: The Takeda Oncology Company today announced its sales force ranked first in an independent assessment of hematology/oncology sales teams in the pharmaceutical industry.
read article 



Association of Community Cancer Centers Publishes Innovative Solutions to the Oncology Workforce Shortage

(ACCC) Sept 14, 2010 - The Association of Community Cancer Centers (ACCC) has published a special edition of its bimonthly journal, Oncology Issues, which provides strategies that oncology care providers can initiate to confront the looming shortages in the oncology workforce.
read press release 



UC Davis Researcher Wins National Award for Role in Breast Cancer Research Innovation

(UC Davis) Sept 15, 2010 - A UC Davis researcher and collaborators from UC San Francisco have received national recognition for groundbreaking work to develop a paperless information system to help speed discovery of new breast cancer therapies.
read press release 



Genentech CEO Leaves Dendreon Board

(Seattle Post-Intelligencer) Sept 14, 2010 - Seattle-based Dendreon said today that Ian Clark, the CEO of Roche's U.S.-based Genentech unit, is resigning from the Dendreon board.
read article 



Notable & Quotable

(Wall Street Journal) Sept 15, 2010 - DNA discoverer James Watson on cancer research.
read article (paid subscription required) 



Special Report: Has Roche Got The Right Medicine?

(Reuters) Sept 15, 2010 - Last summer, the leaders of some of the world's top drugmakers buttonholed Roche Chief Executive Severin Schwan and tried, unsuccessfully, to get him to change his mind.
read article 



UK's NICE Approves Amgen's Prolia For Osteoporosis

(DowJones/MorningStar) Sept 14, 2010 - The U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said it recommended that Amgen's osteoporosis drug denosumab be made routinely available on the publicly funded National Health Service to postmenopausal patients who are at increased risk of osteoporotic bone fractures.
read article 



Diet Drugs Face FDA Scrutiny

(Wall Street Journal) Sept 15, 2010 - A Food and Drug Administration report Tuesday citing safety issues with a proposed obesity drug sent shares of its manufacturer down 40%, the latest setback for a field that once looked like a big money-maker for the pharmaceutical industry.
read article (paid subscription required) 



AstraZeneca's Anticlotting Drug Faces Three-Month FDA Delay

(FOXBusiness) Sept 15, 2010 - U.S. regulators have postponed a key decision on AstraZeneca PLC's experimental blood thinner Brilinta by three months, but the U.K.'s second-biggest drug maker said Wednesday it remains confident about the product's application for market approval there.
read article 



Sanofi Says Genzyme Holders Expect Reasonable Price

(Bloomberg) Sept 15, 2010 - Sanofi-Aventis SA Chief Executive Officer Chris Viehbacher, seeking support for his $18.5 billion bid for Genzyme Corp., said he met with investors who own more than 50 percent of the U.S. company and found they are willing to sell their shares at a reasonable price.
read article 



Despite Cuts, Genzyme Hiring in Mass.

(Boston Globe) Sept 15, 2010 - Even as it moves to shed 1,000 jobs by the end of next year, Genzyme Corp. is accelerating the hiring of manufacturing and quality control workers in Massachusetts, where it recently built a plant in Framingham and expanded its Allston Landing site.
read article (free registration required) 



Does it Matter Where Cancer Patients Die? Study Says Yes

(USA Today) Sept 14, 2010 - In many cases, where cancer patients die may be as important as when they die, at least when it comes to alleviating suffering in patients and the loved ones they leave behind, a new study suggests.
read article